Here’s Why SELLAS (SLS) is Among the 10 Best Performing American Stocks in June 2026

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) is one of the 10 Best Performing American Stocks in June 2026.

On July 6, 2026, Alliance Global analyst James Molloy raised the firm’s price target on SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) to $25 from $10 and kept a Buy rating on the shares. Molloy said the firm is awaiting the final two deaths in the ongoing Galinpepimut-S Phase 3 REGAL trial in acute myeloid leukemia patients achieving second complete remission. Alliance Global views the delay in top-line data as a potentially significant positive, since it suggests patients may be living longer than anticipated on Best Available Therapy in the CR2 AML setting.

Here's Why SELLAS (SLS) is Among the 10 Best Performing American Stocks in June 2026

In May, SELLAS reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. CEO Angelos Stergiou said the first quarter marked an “important period” as SELLAS continued executing across clinical programs while preparing for the anticipated pivotal Phase 3 REGAL trial data readout. Stergiou said the upcoming results, triggered by the pre-specified 80th event, will be an “important milestone” for the company. SELLAS said that as of May 11, 2026, 78 events had occurred in the Phase 3 REGAL trial, with the 80th event set to trigger database lock, blinded data review procedures, statistical analysis, unblinding, and disclosure of topline results. The company also initiated an 80-patient Phase 2 trial of SLS009 in newly diagnosed AML patients, with topline data expected in Q4 2026. SELLAS also established an ATM equity offering under its S-3ASR shelf registration, allowing it to raise up to $150 million over time, and said it has not sold any shares through the ATM to date.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) focuses on the development of novel therapeutics for various cancer indications in the United States.

While we acknowledge the risk and potential of SLS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SLS and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1